Claire Fraser Sells 1,500 Shares of Becton Dickinson and Co (NYSE:BDX) Stock

Share on StockTwits

Becton Dickinson and Co (NYSE:BDX) Director Claire Fraser sold 1,500 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $258.72, for a total transaction of $388,080.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Becton Dickinson and stock opened at $252.23 on Thursday. The firm has a 50-day simple moving average of $272.69 and a two-hundred day simple moving average of $258.73. The company has a market cap of $68.34 billion, a P/E ratio of 92.73, a price-to-earnings-growth ratio of 1.98 and a beta of 1.08. Becton Dickinson and Co has a fifty-two week low of $221.47 and a fifty-two week high of $286.72. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.55 and a current ratio of 0.96.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.63 by $0.02. The business had revenue of $4.23 billion during the quarter, compared to the consensus estimate of $4.19 billion. Becton Dickinson and had a net margin of 4.96% and a return on equity of 15.50%. The company’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.70 earnings per share. Equities research analysts forecast that Becton Dickinson and Co will post 11.97 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be given a $0.79 dividend. The ex-dividend date is Monday, March 9th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.25%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.05%.

Institutional investors have recently modified their holdings of the business. IndexIQ Advisors LLC acquired a new position in shares of Becton Dickinson and during the 4th quarter worth about $25,000. Northwest Investment Counselors LLC acquired a new position in shares of Becton Dickinson and during the 3rd quarter worth about $27,000. Liberty Wealth Management LLC raised its position in shares of Becton Dickinson and by 293.1% during the 3rd quarter. Liberty Wealth Management LLC now owns 114 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 85 shares during the last quarter. Pinnacle Financial Partners Inc. acquired a new position in shares of Becton Dickinson and during the 4th quarter worth about $31,000. Finally, Cedar Mountain Advisors LLC acquired a new position in shares of Becton Dickinson and during the 4th quarter worth about $42,000. Institutional investors and hedge funds own 84.67% of the company’s stock.

Several research firms have commented on BDX. KeyCorp upped their price target on shares of Becton Dickinson and from $284.00 to $298.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Raymond James lowered shares of Becton Dickinson and from a “strong-buy” rating to an “outperform” rating and lowered their price target for the company from $288.00 to $283.00 in a report on Friday, February 7th. Piper Sandler upped their price objective on shares of Becton Dickinson and from to and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Stifel Nicolaus upped their price objective on shares of Becton Dickinson and from $275.00 to $295.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Finally, Cowen downgraded shares of Becton Dickinson and from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $306.00 to $275.00 in a research report on Thursday, February 6th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $279.38.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Buy Rating

Insider Buying and Selling by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ASOS  Upgraded to “Buy” by Berenberg Bank
ASOS Upgraded to “Buy” by Berenberg Bank
Airtel Africa  Receives “Overweight” Rating from Barclays
Airtel Africa Receives “Overweight” Rating from Barclays
Balfour Beatty  Rating Reiterated by Liberum Capital
Balfour Beatty Rating Reiterated by Liberum Capital
Sinclair Broadcast Group  Raised to Hold at Zacks Investment Research
Sinclair Broadcast Group Raised to Hold at Zacks Investment Research
RGC Resources  Upgraded to Strong-Buy by Zacks Investment Research
RGC Resources Upgraded to Strong-Buy by Zacks Investment Research
Brokerages Expect QAD Inc.  Will Post Quarterly Sales of $78.67 Million
Brokerages Expect QAD Inc. Will Post Quarterly Sales of $78.67 Million


 
© 2006-2020 Zolmax.